CA2339406A1 - Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques - Google Patents
Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques Download PDFInfo
- Publication number
- CA2339406A1 CA2339406A1 CA002339406A CA2339406A CA2339406A1 CA 2339406 A1 CA2339406 A1 CA 2339406A1 CA 002339406 A CA002339406 A CA 002339406A CA 2339406 A CA2339406 A CA 2339406A CA 2339406 A1 CA2339406 A1 CA 2339406A1
- Authority
- CA
- Canada
- Prior art keywords
- esk
- sequence
- seq
- polypeptide
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne une nouvelle sous-unité (ESK) du canal potassium et des polynucléotides identifiant et codant ESK. L'invention concerne également des vecteurs d'expression et des cellules hôtes comprenant une séquence d'acide nucléique codant ESK. L'invention concerne en outre des anticorps d'ESK et des méthodes de diagnostic et de traitement d'affections liées à l'expression d'ESK, ainsi que des dosages biologiques de criblage faisant appel aux compositions de polypeptides, de nucléotides et d'anticorps.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9657098P | 1998-08-14 | 1998-08-14 | |
| US60/096,570 | 1998-08-14 | ||
| PCT/US1999/018556 WO2000009534A1 (fr) | 1998-08-14 | 1999-08-13 | Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2339406A1 true CA2339406A1 (fr) | 2000-02-24 |
Family
ID=22257998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002339406A Abandoned CA2339406A1 (fr) | 1998-08-14 | 1999-08-13 | Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1105406A4 (fr) |
| JP (1) | JP2003527818A (fr) |
| AU (1) | AU5487199A (fr) |
| CA (1) | CA2339406A1 (fr) |
| WO (1) | WO2000009534A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094948B2 (en) | 2001-11-14 | 2006-08-22 | Astellas Pharma, Inc. | Transgenic animals |
| US8399663B2 (en) | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
| JPWO2010137689A1 (ja) * | 2009-05-29 | 2012-11-15 | アステラス製薬株式会社 | 注意欠陥／多動性障害新規予防用及び／又は治療用医薬組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401629A (en) * | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| US5328830A (en) * | 1992-09-08 | 1994-07-12 | Miles Inc. | Potassium channel modulators |
| US5599673A (en) * | 1995-03-09 | 1997-02-04 | University Of Utah Research Foundation | Long QT syndrome genes |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| AU1982799A (en) * | 1998-01-23 | 1999-08-09 | Yamanouchi Pharmaceutical Co., Ltd. | Novel potassium channel protein |
-
1999
- 1999-08-13 JP JP2000564984A patent/JP2003527818A/ja not_active Withdrawn
- 1999-08-13 WO PCT/US1999/018556 patent/WO2000009534A1/fr not_active Ceased
- 1999-08-13 CA CA002339406A patent/CA2339406A1/fr not_active Abandoned
- 1999-08-13 AU AU54871/99A patent/AU5487199A/en not_active Abandoned
- 1999-08-13 EP EP99941162A patent/EP1105406A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000009534A1 (fr) | 2000-02-24 |
| EP1105406A4 (fr) | 2004-12-15 |
| JP2003527818A (ja) | 2003-09-24 |
| EP1105406A1 (fr) | 2001-06-13 |
| AU5487199A (en) | 2000-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6303765B1 (en) | Human extracellular matrix proteins | |
| WO1999067382A2 (fr) | Sequences d'un facteur de croissance apparente a l'angiopoietine | |
| US20020061525A1 (en) | Sequences of trail variants | |
| EP0953638A1 (fr) | Canal cationique d'origine humaine homologue au récepteur vanilloide | |
| US6783954B2 (en) | VEGF nucleic acid and amino acid sequences | |
| WO1999010491A1 (fr) | Recepteur couple a la proteine g humaine | |
| CA2339406A1 (fr) | Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques | |
| CA2337835A1 (fr) | Compositions de polypeptides et de polynucleotides de canaux k | |
| AU5843600A (en) | Splice variants of cd40-receptor | |
| WO1998029448A1 (fr) | Proteine liee a une pathogenese humaine | |
| US6610827B1 (en) | Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor | |
| US6506884B1 (en) | Variant of vascular endothelial growth factor | |
| CA2277084A1 (fr) | Proteine humaine de canal de chlorure | |
| EP0936271A1 (fr) | Le gène et la protéine de la sous-unité beta du canal de potassium activé par le calcium | |
| WO1998033913A1 (fr) | Proteine intrinseque humaine | |
| EP1175492A1 (fr) | Homologues de star | |
| WO1998056813A2 (fr) | Deux proteines de fusion membranaire humaines | |
| EP1002863A1 (fr) | Membre de la famille erg des canaux de potassium | |
| WO1999060121A1 (fr) | PROTEINE DU TYPE RECEPTEUR DE GLUTAMATE METABOTROPIQUE ET ADNc DE CODAGE | |
| WO2000044784A1 (fr) | Sequences d'acide nucleique et d'acide amine | |
| WO2001029215A2 (fr) | Homologues de molecules d'adherence cellulaire neuronale | |
| WO1999002680A1 (fr) | Nouvelle proteine regulatrice de croissance humaine | |
| EP1147183A1 (fr) | Nouvelles sequences d'acides nucleiques et d'acides amines | |
| EP0879882A1 (fr) | ATG-1100 (AIF-1-Gamma), une variante d'espissure du AIF-1/RC-9 | |
| US20030100485A1 (en) | Human neurotrimin homolog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |